Cover Image
Market Research Report

Dementia - Pipeline Review, H1 2020

Published by Global Markets Direct Product code 245960
Published Content info 469 Pages
Delivery time: 1-2 business days
Price
Back to Top
Dementia - Pipeline Review, H1 2020
Published: February 28, 2020 Content info: 469 Pages
Description

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dementia - Pipeline Review, H1 2020, provides an overview of the Dementia (Central Nervous System) pipeline landscape.

Dementia is the loss of mental functions such as thinking, memory, and reasoning that is severe enough to interfere with a person's daily functioning. Symptoms include memory loss, hallucinations, agitation, personality changes and difficulty with coordination and motor functions. Risk factors include age, smoking, obesity, high blood pressure, inflammation and cardiovascular diseases.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dementia - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Dementia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dementia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dementia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 9, 24, 22, 54, 24 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 12 and 4 molecules, respectively.

Dementia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Dementia (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Dementia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Dementia (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Dementia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Dementia (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Dementia (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Dementia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Product Code: GMDHC11973IDB

Table of Contents

Introduction

  • Dementia - Overview
  • Dementia - Therapeutics Development
  • Dementia - Therapeutics Assessment
  • Dementia - Companies Involved in Therapeutics Development
  • Dementia - Drug Profiles
  • Dementia - Dormant Projects
  • Dementia - Discontinued Products
  • Dementia - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Dementia, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..3), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..4), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..5), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..6), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..7), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Dementia - Pipeline by Acadia Pharmaceuticals Inc, H1 2020
  • Dementia - Pipeline by Actinogen Medical Ltd, H1 2020
  • Dementia - Pipeline by AcuraStem Inc, H1 2020
  • Dementia - Pipeline by Adamed Sp zoo, H1 2020
  • Dementia - Pipeline by ADEL Inc, H1 2020
  • Dementia - Pipeline by AgeneBio Inc, H1 2020
  • Dementia - Pipeline by Aibios Co Ltd, H1 2020
  • Dementia - Pipeline by Alector Inc, H1 2020
  • Dementia - Pipeline by Alkermes Plc, H1 2020
  • Dementia - Pipeline by Allergan Plc, H1 2020
  • Dementia - Pipeline by Alterity Therapeutics Ltd, H1 2020
  • Dementia - Pipeline by Anavex Life Sciences Corp, H1 2020
  • Dementia - Pipeline by Annovis Bio Inc, H1 2020
  • Dementia - Pipeline by Applied Genetic Technologies Corp, H1 2020
  • Dementia - Pipeline by Aprinoia Therapeutics Inc, H1 2020
  • Dementia - Pipeline by AriBio, H1 2020
  • Dementia - Pipeline by Asceneuron SA, H1 2020
  • Dementia - Pipeline by Axon Neuroscience SE, H1 2020
  • Dementia - Pipeline by Axovant Gene Therapies Ltd, H1 2020
  • Dementia - Pipeline by Axsome Therapeutics Inc, H1 2020
  • Dementia - Pipeline by Biogen Inc, H1 2020
  • Dementia - Pipeline by BioXcel Therapeutics Inc, H1 2020
  • Dementia - Pipeline by Boehringer Ingelheim International GmbH, H1 2020
  • Dementia - Pipeline by Bolder Biotechnology Inc, H1 2020
  • Dementia - Pipeline by Cennerv Pharma (S) Pte Ltd, H1 2020
  • Dementia - Pipeline by Cortice Biosciences Inc, H1 2020
  • Dementia - Pipeline by CSPC NBP Pharmaceutical Co Ltd, H1 2020
  • Dementia - Pipeline by Cyclerion Therapeutics Inc, H1 2020
  • Dementia - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2020
  • Dementia - Pipeline by Denali Therapeutics Inc, H1 2020
  • Dementia - Pipeline by DiaMedica Therapeutics Inc, H1 2020
  • Dementia - Pipeline by Dr. August Wolff GmbH & Co KG Arzneimittel, H1 2020
  • Dementia - Pipeline by Echo Pharmaceuticals BV, H1 2020
  • Dementia - Pipeline by EIP Pharma LLC, H1 2020
  • Dementia - Pipeline by Eisai Co Ltd, H1 2020
  • Dementia - Pipeline by Eli Lilly and Co, H1 2020
  • Dementia - Pipeline by Ensol Biosciences Inc, H1 2020
  • Dementia - Pipeline by Enterin Inc, H1 2020
  • Dementia - Pipeline by EVER Neuro Pharma GmbH, H1 2020
  • Dementia - Pipeline by Galimedix Therapeutics Ltd, H1 2020
  • Dementia - Pipeline by Gismo Therapeutics Inc, H1 2020
  • Dementia - Pipeline by Guangzhou Magpie Pharmaceutical Co Ltd, H1 2020
  • Dementia - Pipeline by GW Pharmaceuticals Plc, H1 2020
  • Dementia - Pipeline by HanAll Biopharma Co Ltd, H1 2020
  • Dementia - Pipeline by Hemostemix Inc, H1 2020
  • Dementia - Pipeline by HSRx Group, H1 2020
  • Dementia - Pipeline by Hyundai Pharmaceutical Co Ltd, H1 2020
  • Dementia - Pipeline by Immungenetics AG, H1 2020
  • Dementia - Pipeline by ImStar Therapeutics Inc, H1 2020
  • Dementia - Pipeline by Inhibikase Therapeutics Inc, H1 2020
  • Dementia - Pipeline by IntraBio Ltd, H1 2020
  • Dementia - Pipeline by iQure Pharma Inc, H1 2020
  • Dementia - Pipeline by IRLAB Therapeutics AB, H1 2020
  • Dementia - Pipeline by Johnson & Johnson, H1 2020
  • Dementia - Pipeline by Kogenix Therapeutics Inc, H1 2020
  • Dementia - Pipeline by LA Cell Inc, H1 2020
  • Dementia - Pipeline by Lachesis Biosciences Ltd, H1 2020
  • Dementia - Pipeline by Luye Pharma Group Ltd, H1 2020
  • Dementia - Pipeline by MediPost Co Ltd, H1 2020
  • Dementia - Pipeline by Mediti Pharma Inc, H1 2020
  • Dementia - Pipeline by Merz Pharma GmbH & Co KgaA, H1 2020
  • Dementia - Pipeline by MGC Pharmaceuticals Ltd, H1 2020
  • Dementia - Pipeline by Neuraltus Pharmaceuticals Inc, H1 2020
  • Dementia - Pipeline by Neurimmune Holding AG, H1 2020
  • Dementia - Pipeline by Neurodyn Cognition Inc, H1 2020
  • Dementia - Pipeline by Neurokine Therapeutics, H1 2020
  • Dementia - Pipeline by NeuroScientific Biopharmaceuticals Ltd, H1 2020
  • Dementia - Pipeline by NLS Pharma Group, H1 2020
  • Dementia - Pipeline by Novartis AG, H1 2020
  • Dementia - Pipeline by Oligomerix inc, H1 2020
  • Dementia - Pipeline by Oryzon Genomics SA, H1 2020
  • Dementia - Pipeline by Otsuka Holdings Co Ltd, H1 2020
  • Dementia - Pipeline by P2D Inc, H1 2020
  • Dementia - Pipeline by Pacific Northwest Biotechnology LLC, H1 2020
  • Dementia - Pipeline by Park Active Molecules, H1 2020
  • Dementia - Pipeline by Passage Bio Inc, H1 2020
  • Dementia - Pipeline by Plico Biotech Inc, H1 2020
  • Dementia - Pipeline by Prevail Therapeutics Inc, H1 2020
  • Dementia - Pipeline by ProMIS Neurosciences Inc, H1 2020
  • Dementia - Pipeline by Prothena Corp Plc, H1 2020
  • Dementia - Pipeline by Psy Therapeutics Inc, H1 2020
  • Dementia - Pipeline by Resverlogix Corp, H1 2020
  • Dementia - Pipeline by SanBio Inc, H1 2020
  • Dementia - Pipeline by Sinfonia Biotherapeutics Inc, H1 2020
  • Dementia - Pipeline by Stemedica Cell Technologies Inc, H1 2020
  • Dementia - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2020
  • Dementia - Pipeline by Suven Life Sciences Ltd, H1 2020
  • Dementia - Pipeline by SyneuRx International Corp, H1 2020
  • Dementia - Pipeline by T3D Therapeutics Inc, H1 2020
  • Dementia - Pipeline by TauRx Therapeutics Ltd, H1 2020
  • Dementia - Pipeline by Theranexus SAS, H1 2020
  • Dementia - Pipeline by UniQure NV, H1 2020
  • Dementia - Pipeline by Voyager Therapeutics Inc, H1 2020
  • Dementia - Pipeline by Wave Life Sciences Ltd, H1 2020
  • Dementia - Pipeline by WhanIn Pharmaceutical Co Ltd, H1 2020
  • Dementia - Dormant Projects, H1 2020
  • Dementia - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Dementia - Dormant Projects, H1 2020 (Contd..2), H1 2020
  • Dementia - Dormant Projects, H1 2020 (Contd..3), H1 2020
  • Dementia - Dormant Projects, H1 2020 (Contd..4), H1 2020
  • Dementia - Dormant Projects, H1 2020 (Contd..5), H1 2020
  • Dementia - Discontinued Products, H1 2020
  • Dementia - Discontinued Products, H1 2020 (Contd..1), H1 2020

List of Figures

  • Number of Products under Development for Dementia, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020
Back to Top